Hutchison China MediTechの機関の所有権
Hutchison China MediTechの機関の所有権は何ですか。
Hutchison China MediTech Ltd.の機関の所有権は47.47%です。
機関の所有権の定義は何ですか。
機関所有権は、ミューチュアル・ファンドまたは年金基金、保険会社、投資会社、その他の資金を管理する他の団体が所有する会社の株式数です。
Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.
Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.
LSEのセクタHealth Careにおける機関の所有権の企業と比べるHutchison China MediTech
Hutchison China MediTechは何をしますか。
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Hutchison China MediTechと類似の機関の所有権
- Stratus Propertiesの機関の所有権は47.43%です。
- Origin Bancorp Incの機関の所有権は47.43%です。
- WiMi Hologram Cloudの機関の所有権は47.45%です。
- House of Control ASの機関の所有権は47.46%です。
- House of Control ASの機関の所有権は47.46%です。
- Starwood Property Trust Incの機関の所有権は47.46%です。
- Hutchison China MediTechの機関の所有権は47.47%です。
- VG Acquisitionの機関の所有権は47.48%です。
- YPFの機関の所有権は47.48%です。
- West Fraser Timber Coの機関の所有権は47.49%です。
- Apollo Hospitals Enterpriseの機関の所有権は47.50%です。
- Dacian Goldの機関の所有権は47.51%です。
- York Water Coの機関の所有権は47.52%です。